A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

NCT00027300 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

NCT00464074 ·Status: COMPLETED

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

NCT00239655 ·Status: TERMINATED ·Phase: PHASE2

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

NCT01945359 ·Status: COMPLETED

ATX-MS-1467 in Multiple Sclerosis

NCT01973491 ·Status: COMPLETED ·Phase: PHASE2

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

NCT01416181 ·Status: TERMINATED ·Phase: PHASE3

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

NCT00097188 ·Status: COMPLETED ·Phase: PHASE2

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.

NCT02746744 ·Status: COMPLETED ·Phase: PHASE3

Natalizumab Subcutaneous Immunogenicity and Safety Study

NCT02142192 ·Status: TERMINATED ·Phase: PHASE2

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT05532163 ·Status: TERMINATED ·Phase: PHASE4

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

NCT06127095 ·Status: COMPLETED

Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response

NCT03316404 ·Status: COMPLETED

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01395316 ·Status: COMPLETED ·Phase: PHASE4

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

NCT05116540 ·Status: COMPLETED ·Phase: PHASE2

The MS-LINK™ Outcomes Study

NCT04735406 ·Status: COMPLETED

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05147220 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702 ·Status: COMPLETED ·Phase: PHASE1

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

NCT05214794 ·Status: COMPLETED ·Phase: PHASE2

MicroRNA-150 and microRNA-155 in Multiple Sclerosis

NCT04300543 ·Status: UNKNOWN

A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis

NCT00087529 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

NCT00468611 ·Status: TERMINATED ·Phase: PHASE3

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

NCT03135249 ·Status: COMPLETED ·Phase: PHASE4

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05925049 ·Status: ACTIVE_NOT_RECRUITING

COMparison Between All immunoTherapies for Multiple Sclerosis.

NCT03193866 ·Status: COMPLETED